Definition of Suspicious Lesion(s)
If you retrieved virus on day of ocular splash, and if case is confirmed with a vaccinial lesion lasting several days, individual is considered immunized.
Link to photos
Inadvertent inoculation, includes ocular
Types of Eye Involvement
Treatment for Periocular Involvement
Periocular lesions only (no lid involvement or lesions in eye)
Treatment for Blepharitis
Treatment for Conjunctivitis
Mild Conjunctivitis (no visible lesions in or near the eye)
Mild Conjunctivitis with suspicious lesions in or near the eye (no corneal lesions)
Severe Conjunctivitis with suspicious lesions in or near the eye (no corneal lesions)
Treatment for Keratitis only
Treatment for Keratitis with mild or moderate blepharitis or conjunctivitis
Keratitis with mild or moderate blepharitis or conjunctivitis
Treatment for Keratitis with severe blepharitis and/or conjunctivitis
Keratitis with severe blepharitis and/or conjunctivitis
VIG consultation call (888) USA-RIID or (301) 619-2257.
Multidisciplinary Case Discussion via Conference Call
MILVAX-VHCN Clinical Services
will arrange multidisciplinary conference call
The following information will be provided to participants:
[Should you need assistance during your conference, please press # then 0 for a list of menu options including Specialist assistance.]
MILVAX-VHCN Clinical Services Physician:
Duty hours: 202-782-0411
Non-duty hours: Call DoD Vaccine Clinical Call Center at (866) 210-6469 for provider and number
Available Topical antiviral agents
Trifluridine (Viroptic®) and vidarabine (Vira-A®) are not approved by FDA for treatment of vaccinia disease,
although the product labels for trifluridine and vidarabine state that the drugs have in vitro and in vivo activity against vaccinia virus.
Vidarabine is no longer being manufactured, but supplies might be available in certain areas.
Cidofovir, which is active against orthopox viruses and suggested for possible treatment of smallpox, has not been evaluated for use in ocular vaccinia or keratitis.